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Abstract
Background: Changing clinical impact, as virulent clones replace less virulent ones, is a feature of many pathogenic
bacterial species and can be difficult to detect. Consequently, innovative techniques monitoring infection severity are of
potential clinical value.
Methods and Findings: We studied 5,551 toxin-positive and 20,098 persistently toxin-negative patients tested for
Clostridium difficile infection between February 1998 and July 2009 in a group of hospitals based in Oxford, UK, and
investigated 28-day mortality and biomarkers of inflammation (blood neutrophil count, urea, and creatinine concentrations)
collected at diagnosis using iterative sequential regression (ISR), a novel joinpoint-based regression technique suitable for
serial monitoring of continuous or dichotomous outcomes. Among C. difficile toxin-positive patients in the Oxford hospitals,
mean neutrophil counts on diagnosis increased from 2003, peaked in 2006–2007, and then declined; 28-day mortality
increased from early 2006, peaked in late 2006–2007, and then declined. Molecular typing confirmed these changes were
likely due to the ingress of the globally distributed severe C. difficile strain, ST1. We assessed the generalizability of ISR-based
severity monitoring in three ways. First, we assessed and found strong (p,0.0001) associations between isolation of the ST1
severe strain and higher neutrophil counts at diagnosis in two unrelated large multi-centre studies, suggesting the
technique described might be useful elsewhere. Second, we assessed and found similar trends in a second group of
hospitals in Birmingham, UK, from which 5,399 cases were analysed. Third, we used simulation to assess the performance of
this surveillance system given the ingress of future severe strains under a variety of assumptions. ISR-based severity
monitoring allowed the detection of the severity change years earlier than mortality monitoring.
Conclusions: Automated electronic systems providing early warning of the changing severity of infectious conditions can
be established using routinely collected laboratory hospital data. In the settings studied here these systems have higher
performance than those monitoring mortality, at least in C. difficile infection. Such systems could have wider applicability for
monitoring infections presenting in hospital.
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Introduction
Bacterial diseases remain one of the most important causes of
illness in humans. The genomes, and consequently the clinical
behaviours, of many important human pathogens are constantly
changing [1–4]. Although much previous work has focused on
evolving antimicrobial resistance, evolving virulence in successful
microbes is also well recognised [5]. One recent example is the
global outbreak of ribotype 027/NAP1/ST1 C. difficile [6–9], in
which derepressed toxin production led to enhanced disease
severity relative to non-027 strains.
Indeed, continuing genotypic and phenotypic change is
probably the rule, rather than the exception, within bacterial
species [10]. General methods of detecting changing virulence that
would permit early recognition, control, and optimal management
of such threats would therefore be highly desirable.
Recent investments in information technology systems in the
UK National Health Service, and other large health care providers
worldwide, have allowed electronic collection of large amounts of
patient data. Such collections typically include various laboratory
measurements, in addition to hospital admission and diagnosis
data. Changes in parameters, such as peripheral blood white cell
and neutrophil counts, urea and creatinine concentrations, can be
consequences of an innate response to infection present in all
humans [11]. Such changes are known to reflect illness severity in
many infections [12–15], and form part of generally applicable
critical illness scoring systems including APACHE [16].
Since full blood count and renal function measurements are, at
least in high-income countries, measured frequently on diagnosis
[17], we investigated whether they might form the basis of an
infection severity surveillance scheme. We illustrate our approach
with an investigation of the changing virulence of C. difficile
infection (CDI), using data from Oxford Radcliffe Hospitals NHS
Trust (ORH), UK.
Methods
Data from Oxford and Ethics Statement
We considered all positive C. difficile toxin tests obtained in the
ORH microbiology laboratory, excluding positive tests within
28 d of a previous positive as a duplicate, according to UK
Department of Health guidance [18]. We then identified all
inpatients over 18 y of age, with a positive C. difficile test whilst
admitted to the ORH NHS Trust between 1 February 1998 and 1
August 2009, their associated demographics and hospital admis-
sions prior to the admission with C. difficile. The 1998 start date
was based on availability of admission data, and the 2009 end date
was the time at which the creatinine analysis method used in the
hospital changed.
For haematology and biochemical data, we identified the
laboratory blood test results closest to the C. difficile test sample,
within a window extending from 48 h before to 48 h after
sampling.
Prior to 1 October 1999, cell-culture-based toxin testing was
performed; subsequently, testing used an A+B toxin enzyme
immunoassay (Meridian Biosciences). In response to the
recognition of an increase in severity in C. difficile, from
October 2006 onwards, C. difficile culture was attempted on all
faecal samples with positive toxin tests, C difficile isolates stored,
and results of multilocus sequence typing [19] were available
for toxin-positive culture-positive samples [20,21]. From May
2007, a change in government policy [18] specified mandatory
testing of all unformed stool samples submitted from patients
over 65 y, irrespective of perceived clinical risk (whether the
patient met local criteria for diarrhoea of $3 unformed stools
in 24 h).
We excluded patients admitted to oncological and renal
specialities, since their laboratory values are likely to reflect their
underlying diagnosis, rather than the impact of C. difficile, and, for
similar reasons, patients with creatinine ,16 or .800 mmol/l,
neutrophil counts ,16109/l (neutropenia) or .406109/l, and
lymphocyte counts .106109/l.
All remaining cases were analysed for changes in mortality and
incidence over calendar time. Biomarker analyses were restricted
to cases with the relevant blood test results. To decrease influence
of outliers, for biomarkers with no prior count restriction, values
below the 1st percentile and above the 99th percentile were
excluded from the analysis.
We considered patients with only toxin-negative samples as a
control group. We excluded patients with any subsequent positive
tests to minimise the impact of false negatives. A 28-d deduplica-
tion was also made for negative tests, and the same inclusion/
exclusion criteria were applied.
The data were extracted from an anonymised linked electronic
research database, the Infection in Oxfordshire Research Data-
base (IORD), approved by the Oxford Research Ethics Commit-
tee (09/H0606/85) and the National Information Governance
Board (5-07(a)/2009).
A STROBE checklist is attached as Text S1.
Data from Birmingham and Ethics Statement
Anonymised microbial isolation and biomarker data were
extracted from information systems in the University Hospitals
Birmingham NHS Foundation Trust (UHB), in order to assess
infection severity in the Queen Elizabeth Hospital and Selly Oak
Hospital, Birmingham, at the end of this investigation. UHB is a
major tertiary referral centre, organisationally distinct from the
Oxford centre, being located about 100 km to the north. These
hospitals operate a wide range of medical and surgical services, but
not obstetric or paediatric services. As in Oxford, toxin-based
testing operated as the diagnostic method throughout the period
observed. Data were available from 1 January 2000 onwards, and
we deduplicated, selected, and excluded biomarker data as for the
Oxford dataset; we used the same end date for analysis as for the
Oxford cohort analysed.
Statistical Methods
We used general linear regression models to estimate changes in
mean of potential biomarkers of severity over calendar time. Given
the known biology of C. difficile infection, we initially investigated
neutrophils, creatinine, urea, and albumin, with the aim of
identifying whether any marker showed similar calendar trends to
those in post-infection mortality and/or indicated the known
ribotype 027/ST1 epidemic, which was identified during 2005.
Biomarker data were transformed to achieve normality using the
Box-Cox method [22], and modelled using normal linear
regression; 28- and 7-d mortality were modelled using logistic
regression. A gridsearch algorithm, essentially as described [23],
was used to identify changes in trends (such as apparent increases
or decreases), considering all possible 0- to 4-joinpoint models with
joinpoints fitted every 3 mo. The best fitting model was chosen on
the basis of the Bayesian Information Criterion (BIC) [24], and
models with BIC within 3.84 of the best fit [23] were considered
statistically indistinguishable.
To estimate how soon any changes in biomarker/mortality
trends would have been detected, we used an iterative sequential
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regression (ISR) technique. Specifically, we reconstructed what
would have been observed if the data had been monitored in real-
time, and applied gridsearch to sets of samples taken between 1
February 1998 and 1 September 1998, and successively every
month through 1 August 2009. On each dataset a one-trend and a
succession of two-trend models were fitted, with iterative selection
of optimal joinpoints (see Text S2). Admission neutrophil counts
(Box-Cox transformed) in the 027/NAP1/ST1 epidemic clone
versus other C. difficile strains were compared using t tests.
To evaluate the severity monitoring techniques, we performed
two simulation studies in which we assumed a more severe strain
of C. difficile (analogous to ribotype 027/NAP1/ST1) was
introduced into a hospital.
The studies assessed the influence of key parameters (additional
virulence of the new strain compared to underlying variability in
biomarker measurements, penetrance of the new strain, number of
affected patients per year) on the following outcome measures: (a)
With what probability is the arrival of the severe strain detected?
This key operational question was addressed using the ISR
method. Data were simulated on the basis of the assumption that
after 1 y of constant virulence, a new, more severe, strain was
introduced, and during year 2 it replaced existing strains, fully or
partially, at a constant rate. The change was deemed ‘successfully
detected’ if the best model suggested that the rates were increasing
significantly (p,0.05) at the study end. (b) If the severe strain
arrives, peaks, and then declines (as occurs with successful control),
with what probability is control of the outbreak observed? We
assumed that during year 1, a new strain arrived and replaced
existing ones, as above, and during year 2 it decreased at the same
rate. This question is predominantly of retrospective interest; data
were analysed using the gridsearch method applied to 0- and 1-
joinpoint models. The change was deemed ‘successfully detected’ if
the best model contained one joinpoint, located within 6 mo from
the real one, and rates decreased significantly (p,0.05) at the
joinpoint.
Simulation model parameters were derived from the study data
(see Text S2 for details). The R language (2.11 for Windows) was
used for data visualisation (ggplot2 package), modelling (glm and
survival package), and simulation. The source code used in the
study can be obtained from http://www.infectionsurveillance.org.
Results
Patients Studied
After 28-d deduplication, there were 8,357 C. difficile toxin-
positive samples from 7,272 adults tested at the ORH NHS Trust
between February 1998 through July 2009. We excluded 2,152
cases that were out of hospital and three cases from community
hospitals leaving 6,202 samples, of which further 534 cases from
renal/oncology specialties and 117 cases with extreme neutrophil,
creatinine, and lymphocytes levels were removed (see Methods),
leaving 5,551 cases for mortality and incidence analyses. A further
74 cases with extreme urea levels were removed from urea analyses.
As a control group, to address possible secular trends in laboratory
methods or type of patients tested for C. difficile, we used 20,098
deduplicated, and similarly filtered, toxin-negative samples from
17,376 patients who never had a positive test. Demographic details
of the C. difficile cases and negative controls are presented in Table 1.
Changes in incidence over time were similar to national trends
[8], increasing from ,10/10,000 overnight stays in 1998 to ,16/
10,000 overnight stays at the beginning of 2006, then declining back
to ,8/10,000 overnight stays in July 2009 (numbers of cases are
shown in Table 1). As noted in Methods, from 2007 onwards,
increased testing occurred in low-risk, over 65-y-old patients as
required by government policy; this, however, appeared to have
little, if any, effect on case demographics (Table 1, and unpublished
data). 38% of cases and 34% controls had missing albumin,
compared to #28% missing data for other biomarkers, and so
albumin was not considered further. We found no association
between 28-d mortality and missing biomarker values (p.0.4).
Routinely Collected Data Are Associated with Mortality
Elevated levels of neutrophils and creatinine have been reported
to be associated with CDI severity and mortality [25]. We
confirmed these associations, and an association between raised
urea and mortality, in our C. difficile–positive cases (Figure 1).
Secular Changes in C. difficile-Associated Severity
Markers, Incidence, and Mortality
Figure 2 shows secular trends in quarterly 7- and 28-d post-
infection mortality, and mean neutrophils and urea at CDI
diagnosis, over 1998–2009. Notably, persistent elevation in mean
neutrophil count at C. difficile test between 2005 and 2007 in the C.
difficile–positive cases is suggested both visually and by loess fitting;
trends in mortality were much less apparent, although possibly
greater in 7- than 28-d mortality. No equivalent trends were
evident in the negative control group for any outcome. There were
no obvious trends in urea or creatinine (unpublished data) at CDI
diagnosis.
Retrospective Data Analysis Using Gridsearch Method
The introduction of new strains is often characterised by
gradual changes over years [2–4]. We therefore used linear models
with joinpoints to approximate changes in outcomes over the
entire period of the study, as previously done for methicillin-
resistant Staphylococcus aureus (MRSA) [23]. Up to four joinpoints
were permitted (Figure 3).
No trend changes in 7-d mortality were identified: rather 7-d
mortality was estimated to have increased slightly but non-
significantly over the whole study period (p=0.8). By contrast, the
same analyses applied to 28-d mortality detected one single peak,
with 28-d mortality increasing sharply from August 2005 through
November 2005 and then declining, with statistically indistin-
guishable models suggesting either that the rise started between
May 2002–November 2005, or that 28-d mortality had been
increasing gradually but steadily from the start of the study period.
In the best model mean neutrophils started to increase from
2004 (with statistically equivalent models supporting the increase
starting between August 2003–February 2005), peaked in 2006
(February 2006–May 2007), and subsequently declined until late
2008 (November 2007–February 2009). Further, some models
suggested a weaker earlier rise peaking in 1999 (May 1999–
February 2000). Differences between models close (within 3.84 of
BIC) to the best model (solid line) were small, with all models
identifying a peak in severity in 2006–2007. Similar results were
obtained adjusting for age, gender, and previous hospital exposure
(unpublished data), suggesting that this biomarker is informative
about severity over and above the demographic information.
Similar trends were not found in the negative control group
(unpublished data), confirming the observed changes are C. difficile
specific.
The same analysis applied to urea found no evidence of any
secular trends, with urea decreasing non-significantly (p=0.16)
over the study period, also suggesting that changes in neutrophils
could be strain-specific rather than due to other changes in case-
mix (Figure 3). Results for creatinine were broadly similar to
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neutrophils, but with greater intrinsic variability in this biomarker
giving less certainty about changes.
Using ISR Technique for Monitoring Purposes
We used the ISR technique to investigate whether it would have
been feasible to use the host response data rather than (or in
addition to) post-infection mortality to monitor changes in
microbial severity on a regular monthly basis (Figure 4). As across
the whole study period, monthly monitoring detected no trend
changes at all in 7-d mortality. In contrast, analysis of 28-d
mortality identified decreasing mortality after November 2006
only in October 2008. The first time that monthly monitoring
would have identified that 28-d mortality was increasing
significantly (p,0.05) was March 2006.
In contrast, for neutrophil counts we found that an increasing
trend from February 1998 changing to a decreasing trend would
have been detected in December 2001, with some uncertainty
around the exact time of change (April 1999–October 2000), most
likely time being January 2000. Interestingly, there was actually an
increasing trend in 28-d mortality from February 1998 through
January 2000 that did not reach statistical significance (odds ratio
[OR]=1.02 per year, p=0.3).
A new rise in neutrophil levels from February 2003 (January
2003–February 2003) would have been detectable only 3 mo later,
in May 2003. Clinically, the ingress of the severe strain into the
Oxford hospitals was not detected before national alerts were
issued 3 y later and enhanced typing was established in 2006.
Neutrophils continued to rise until September 2006 (March 2006–
June 2007). The downward change in trend became observable
after a year, in September 2007. Intriguingly, the analysis suggests
another rise started in late 2008 (p=0.001); molecular analysis of
these cases is ongoing. We found no evidence of changes monitoring
urea monthly between 2002 and 2009, although there was weak
evidence supporting an earlier rise and then decline in 2000 (statistical
Table 1. Demographics of the patients studied.
Patient Group Factor Subcategory n (%) or Median IQR
01/02/
1998–2000 2001–2003 2004–2006
2007–01/
08/2009 Total
C. difficile–
positive cases
Total n cases 1,043 (100%) 1,638 (100%) 1,790 (100%) 1,080 (100%) 5,551 (100%)
Sex Male 440 (42%) 730 (44%) 811 (45%) 463 (42%) 2,444 (44%)
Age at admission y 76 (71–86) 76 (71–86) 77 (72–86) 74 (67–85) 76 (71–86)
Previous ORH
admission
In the past year 571 (54%) 907 (55%) 1,158 (64%) 720 (66%) 3,356 (60%)
Admission
specialty codes
General medicine 581 (55%) 985 (60%) 1,110 (62%) 624 (57%) 3,300 (59%)
Other medicine 226 (21%) 268 (16%) 186 (10%) 90 (8%) 770 (13%)
General surgery 65 (6%) 134 (8%) 152 (8%) 127 (11%) 478 (8%)
Trauma and orthopaedic 33 (3%) 63 (3%) 54 (3%) 40 (3%) 190 (3%)
Other specialties 138 (13%) 188 (11%) 288 (16%) 199 (18%) 813 (14%)
Missing data Neutrophil count 330 (31%) 578 (35%) 393 (21%) 144 (13%) 1,445 (26%)
Urea 371 (35%) 621 (37%) 431 (24%) 176 (16%) 1,599 (28%)
Creatinine 278 (26%) 531 (32%) 351 (19%) 138 (12%) 1,290 (23%)
Albumin 460 (44%) 736 (44%) 630 (35%) 313 (28%) 2,139 (38%)
C. difficile–
negative controls
Total n cases 3,121 (100%) 4,330 (100%) 5,142 (100%) 7,505 (100%) 20,098 (100%)
Sex Male 1,339 (42%) 1,933 (44%) 2,256 (43%) 3,388 (45%) 8,916 (44%)
Age at admission y 68 (57–83) 69 (58–82) 69 (58–83) 70 (60–84) 69 (58–83)
Previous ORH
admission
In the past year 1,417 (45%) 2016 (46%) 2,675 (52%) 3,934 (52%) 10,042 (49%)
Admission specialty General medicine 1,420 (45%) 2,043 (47%) 2,529 (49%) 3,556 (47%) 9,548 (47%)
Other medicine 664 (21%) 709 (16%) 687 (13%) 797 (10%) 2,857 (14%)
General surgery 374 (11%) 616 (14%) 757 (14%) 1,049 (13%) 2,796 (13%)
Trauma and orthopaedic 117 (3%) 163 (3%) 168 (3%) 339 (4%) 787 (3%)
Other specialties 546 (17%) 799 (18%) 1,001 (19%) 1,764 (23%) 4,110 (20%)
Missing data Neutrophil count 922 (29%) 1,274 (29%) 1,024 (19%) 1,182 (15%) 4,402 (21%)
Urea 1,095 (35%) 1,389 (32%) 1,097 (21%) 1,462 (19%) 5,043 (25%)
Creatinine 779 (24%) 1,153 (26%) 872 (16%) 1,094 (14%) 3,898 (19%)
Albumin 1,301 (41%) 1,743 (40%) 1,599 (31%) 2,259 (30%) 6,902 (34%)
doi:10.1371/journal.pmed.1001279.t001
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significance of the change in trend decreased from p,0.001 at the
detection time to p=0.2 at the end of the study period).
Thus, enhanced severity of C. difficile cases peaking around 2006
was strongly suggested by passive monitoring of routine laboratory
data using ISR, an efficient joinpoint-based regression method
suitable for regular monitoring. Biomarker trends predicted by
ISR were broadly similar to those from a much more computa-
tionally intensive gridsearch method (Figure 3).
Non-Parametric Modelling
We investigated whether changes in severity markers might
have been more noticeable in only a subset of the population, such
as patients with more severe infection, using non-parametric
(quantile) regression for the 75th and 90th quantiles. Both
gridsearch and ISR techniques detected the 2000 and the 2006
peaks for neutrophil counts. However, in some models multiple
additional joinpoints were suggested (unpublished data), as a
consequence of more variability in these quantiles.
Prediction of Enhanced Virulence Confirmed by
Molecular Typing
One explanation for the observations of increased neutrophil
counts in those with CDI is that the strain(s) of C. difficile prevalent
in 2006 exhibited enhanced virulence relative to those in 2003. A
multi locus typing scheme (MLST) was established in late 2006
(see Methods). During the first full year of this program (2007), as
the neutrophil severity signal was beginning to decline (above), full
blood count data and typing information were available on 409
patients with culture confirmed C. difficile (Figure 5). Mean
neutrophil count among the 167 ST1 cases was 13.56109/l,
while in the 245 non-ST1 isolates it was 10.76109/l (difference in
means 2.8 [95% CI 1.5–4.5], p=0.0001). Quantile regression gave
an almost identical estimate (2.8, 95% CI 1.50–4.61). Thus,
comprehensive typing in one large group of hospitals suggests the
ingress of the virulent 027/NAP1/ST1 C. difficile strain is the most
likely explanation for the elevation in neutrophil counts. It further
suggests the onset of the epidemic of severe disease began in
Oxfordshire in around 2003.
Generalizability of the Technique
To ascertain whether the biomarker-monitoring technique we
have described could be generally applicable, we performed three
further investigations. Firstly, we determined whether the
biomarker:severe strain association observed in Oxford was
present in other settings. Secondly, we performed simulation
studies to assess its likely performance in future outbreaks in other
settings, relative to the monitoring of mortality. Thirdly, we
analysed the trends in severity-associated biomarkers in another
hospital using the ISR technique.
Multi-centre Investigation into the Neutrophil: Strain-
Type Association
We examined unpublished associations between admission
biomarker and microbial culture data from two pivotal phase III
double-blind randomized non-inferiority licensing trials (studies
003 and 004) of oral fidaxomicin versus vancomycin in the
treatment of C. difficile disease [26,27]. Recruitment was predom-
inantly from North America: Study 003 recruited from 62 sites in
North America, whereas study 004 recruited from 86 sites: 41
from US and Canada, and 45 from Europe.
Eligibility criteria in the 003/004 studies involved ELISA-based
toxin testing, rather than culture. Organisms were cultured and typed
from a proportion of the patients included, as discussed [26,27]. PCR
ribotyping was used as a typing method [26] rather than MLST, but
PCR-ribotype 027 has been shown consistently to be ST1 (and vice
versa) [19,28]. The non-cultured cases did not differ systematically
from the culture positive cases (unpublished data).
Figure 1. Association between biomarkers and mortality in C. difficile-positive patients. The association between mortality within 7 d
(triangles) or 28 d (circles) and three biomarkers measured on admission (peripheral blood neutrophil counts6109/l, left, serum urea concentrations
(middle, mmol/l), and serum creatinine concentrations (mmol/l, right) are illustrated among the 5,551 cases from the Oxford centre. For each
biomarker, patients were divided into deciles of equal size. Each point represents the observed (and 95% CIs around) mortality for patients. Mortality
increases as neutrophil and urea concentrations rise. This is also true for creatinine concentrations over about 100 mmol/l.
doi:10.1371/journal.pmed.1001279.g001
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Of the cases who had both culture results and admission
blood counts available, there were 600 North American
patients, 293 from the US and 307 from Canada. The European
group, which was smaller (n= 123, of which 22 were from
ORH) was not analysed further because of overlap with the
previous study.
Figure 5 shows mean neutrophil count among the cases with the
027 severe strain was significantly higher in both US and
Canadian patients than in cases with other strains 9.36109/l,
and 10.16109/l, respectively, while in the non-027 cases it was
7.76109/l and 6.86109/l, respectively (t test, p,161024 and
0.01, respectively). Non-parametric rank-sum testing produced
similar conclusions (p=0.002, p=0.01, respectively). Thus, the
difference between severe strain biomarkers was found in diverse
sites, suggesting severity biomarker monitoring may be widely
applicable. The mean counts were somewhat lower in the 003/
004 studies than in the Oxford typing series, although the
difference between the strains is very similar. This is likely due to
both the younger age in the 003/004 studies (mean 62 y)
compared to ORH (mean 75 y), and trial eligibility criteria,
particularly the need for written informed consent and the
exclusion of very severe cases [26,27].
Figure 2. Secular changes in mortality and potential C. difficile-associated severity biomarkers. Mean quarterly mortality, neutrophil
counts (6109/l), and urea concentrations (mmol/l) between 1998 and 2009 in C. difficile-positive cases (left panel) and C. difficile-negative controls
(right panel) with 95% CIs for each quarter shown as error bars. The black curved lines represent fitted loess curves with the span parameter set to 0.5
to capture the shape of the underlying data. Inspection suggests a rise in neutrophil counts among positive cases between 2004–2009, concomitant
with a rise in 28-d mortality. There is also a suggestion of a rise in neutrophil counts among cases presenting in 1999–2000 relative to 2001–2003.
Similar changes were not observed in C. difficile–negative cases.
doi:10.1371/journal.pmed.1001279.g002
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Simulation Studies
To further assess the potential of the severity surveillance
techniques described, we simulated two scenarios (see Methods):
one in which a new, severe organism invades a hospital (Figure 6a),
and a second in which it first invades, and then declines, for
example due to effective infection control (Figure 6b).
Based on realistic simulation parameters derived from our
observed data (see Text S2), the performance of biomarker-based
detection was notably higher than that of post-infection mortality
monitoring. To illustrate, if the new strain had been four times as
virulent as the original 027/NAP1/ST1 strain and increased to
50% of circulating strains, biomarker monitoring would have
identified its arrival in 96% cases, as opposed to 20% with
mortality monitoring (Figure 6a).
As expected, increased virulence and/or penetration of the new
strain results in changes being detected more often, regardless of
monitoring method. For example, the arrival of a strain with 2-fold
increased virulence would have been detected in ORH in 76% as
opposed to 30% cases for the baseline case (Figure 6a). However, in
an ORH-sized hospital, a new organism would have needed to have
been four times as virulent and have increased to 100% penetrance to
have been detected in .50% cases using 28-d mortality monitoring.
Enhanced power could also be achieved using a multi-centre
network of hospitals. For example, a 10-fold increase in the
Figure 3. Analysis of secular trends over the whole study period using retrospective gridsearch. The best model for quarterly mortality,
neutrophil counts, and urea over the whole study period (solid line) was chosen on the basis of BIC, see Methods. Models with BIC within 3.84 of the
best fit were considered statistically equivalent, and variation in the estimated joinpoints across these models are indicated by the horizontal intervals
around the joinpoint from the best model (indicating a change from an upward to downward trend bym, and from a downward to an upward trend
by .). Any equivalent models with fewer or greater joinpoints than the best model are shown with dashed grey lines.
doi:10.1371/journal.pmed.1001279.g003
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hospital-monitored population would have resulted in a 92%
detection rate for control of a new organism, in comparison with
the 16% detection rate of the baseline case (Figure 6b).
The rate of identifying (false-positive) changes in the simulations
with no new strain remained under 5% in both simulations.
Studies of Trends in Other Hospitals
Finally, we used the ISR technique to analyse trends in
neutrophil counts in a second major UK hospital, based in
Birmingham. Data were not available prior to 2000 in this centre.
Following exclusions identical to those operating in Oxford, there
were 5,399 cases available for analysis.
Data are presented over the same time frame as used for the
Oxford study (Figure 7).
Interestingly, a decline in neutrophil counts on presentation was
seen in the Birmingham centre from 2000–2003, as was observed
in Oxford, compatible with a period of increased severity of C.
difficile in the UK around 2000. Similar to the Oxford centre, an
increase in severity was observed from 2003 onwards, and which
was detected by the ISR algorithm, although with some
uncertainty about the change point. Visual inspection suggests
that, as in Oxford, neutrophil counts declined after a peak in or
around 2007 to 2008. The change downwards is not detected by
ISR in the data shown in Figure 7, although it was detected in
subsequent data (unpublished data).
Figure 4. Analysis of secular trends month by month using ISR. Cumulative data on mortality, neutrophils and urea modelled successively to
each month, as if such monitoring had been conducted in real-time, see Methods. Changes in secular trends identified by ISR indicated bym (change
from an upward to downward trend), and . (a downward to an upward trend), with+indicating the point in time when this change in secular trend
was first detected, and horizontal intervals showing the range of joinpoints within 3.84 of the best model BIC at this time.
doi:10.1371/journal.pmed.1001279.g004
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In summary, similar trends in severity are observed in two UK
hospitals, and are detected by the ISR algorithm.
Discussion
In this study of infection severity surveillance, we used C. difficile
disease as an example, because enhanced virulence associated with
emergence of a new strain (027/NAP1/ST1) was known to have
occurred historically. Widespread clinical recognition of clone
impact, including in Oxford Radcliffe Hospitals, occurred in 2006;
retrospectively, the clone was detected in stored samples across
Europe from 2003 onwards [8,9], the same time that passive
monitoring of neutrophils would have suggested a significant
increase in infection severity in our hospitals. This evidence that
the 027/NAP1/ST1 strain caused the severe disease observed is
supported by experimental studies in animals [7,27,29].
For evaluation of our passive surveillance technology, we mainly
focused on neutrophil counts on diagnosis, because of their
frequent measurement prior to therapy, and their known
association with mortality in C. difficile colitis [8], something also
seen in our study. We elected not to study measures that could be
influenced by secular trends in either clinical practice or
therapeutic efficacy, such as duration of stay or speed of resolution
of host response.
Visual inspection, gridsearch, and ISR analyses of passively
collected laboratory measures of severity (neutrophil counts and, to
a lesser extent, creatinine) were all highly suggestive of rising
pathogen virulence from 2003–2004 to 2006, followed by
virulence decline. The prediction that these changes were due to
ingress of the highly virulent ribotype 027/NAP1/ST1 strain is
supported by detailed molecular typing data in one centre.
Further, such severe strain-associated biomarker associations were
also found in two clinical trials performed across multiple
hospitals, and are compatible with published literature from
diverse sites [6–8,30]. Similar secular trends in biomarkers were
observed in another large hospital group. Together, these data
support the generalizability of the initial observations from a single
large hospital group.
The likely utility of the biomarker-monitoring technique
described here has been assessed by simulation. Importantly,
analysis of both the historical outbreak, and of future simulated
outbreaks, shows monitoring of post-infection mortality, as
opposed to laboratory measures of severity on diagnosis, affords
much less confident detection. This probably reflects the relatively
low attributable mortality of C. difficile [31], and the lesser
statistical power inherent in use of a dichotomous, rather than
continuous, variable.
Interestingly, in addition to the known 2006 outbreak,
regression models suggest another rise of neutrophil counts
peaking around 2000, which was seen in two hospitals. This
suggests that waves of virulence may be a recurring feature of C.
difficile, something compatible with observed ongoing heterogene-
ity of virulence in the C. difficile population [32]. However, the
basis of the earlier severity peak remains speculative, as typing data
are not available from 2000.
Figure 5. Validation of predictions of passive surveillance: molecular typing data from ORHs and from the 003/004 studies.
Flowchart (A) illustrates laboratory and typing data available for consecutive faecal samples with positive C. difficile toxin tests in the Oxford site
during the 2007 calendar year. Diagnosis peripheral blood neutrophil counts in ST1/NAP1/027 versus non-ST1/NAP1/027 cases are shown for three
cohorts: Oxford in 2007, US patients entered into the 003/004 fidaxomicin studies, and Canadian patients entered into the same trials. (B) Means and
standard errors in each group are shown, as are (C) 95% CIs around the difference between ST1/NAP1/027 versus non-ST1/NAP1/027 cases.
doi:10.1371/journal.pmed.1001279.g005
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Generalizability
To what extent would one expect this kind of biomarker-based
surveillance to be generalizable to other organisms and conditions?
It requires that there exists at least one routinely collected
biomarker that is associated with disease-related mortality for each
target condition. This is likely to be true for many infections;
measures of renal function (urea, creatinine), glucose levels,
platelet counts, measures of deranged liver function (transaminas-
es, etc.), and coagulation status have all been shown to be
prognostic in various infections [12–16,33]. Indeed, such bio-
markers are well recognised in studies of all-cause critical illness
cohorts, further supporting the likely generalizability of the
technique [16]. In practice, we envisage that initially a number
of potential severity markers could be investigated for each
infection, retrospectively using historical data if available, or
prospectively based on routine electronic databases. Comparing
historical data with mortality retrospectively, and/or investigating
any ‘‘signals’’ prospectively, would identify which biomarkers were
most useful for passive severity monitoring.
With all surveillance systems, the populations monitored need to
be carefully defined. Obviously, choosing to run analyses on
poorly defined subgroups (or outcomes) may result in ‘effect
dilution’ if severity change only occurs in part of the population
studied; our simulation studies, presented here, will allow readers
to judge the likely impact of such effect dilution in their
populations.
Limitations
Routine monitoring of laboratory measures of severity has
limitations. One concerns feasibility. The samples used to predict
severity were routinely collected, and came from inpatients;
although in many hospitals in high-income countries such samples
are taken in the majority of admissions, this may not be the case in
less resourced settings.
A less obvious issue is biological, and concerns the constancy of
the biomarker:mortality relationship. Inter-human variation is a
contributor to the noise in this relationship [26], but the
surveillance technique described here can operate successfully
despite this, given adequate sample numbers. It is possible that
harmless strains of common microbes might exist that enhance
biomarkers but do not enhance mortality, or perhaps vice versa. In
practice, innate immune microbial recognition, which drives many
of the biomarkers whose changes we suggest could be monitored,
is multi-faceted [6], and strong selective pressures have operated
over millennia to consistently detect and respond in a protective
manner to all pathogens [6]. Consequently, we suspect differential
Figure 6. Simulation studies investigating the impact of virulence, penetrance, and study population size on monitoring
performance. The study parameters included size of the hospital(s) being monitored (left panel), additional virulence of the new strain relative to
biomarker variability (central and right panels); and maximal penetrance of the new strain (all panels, effect represented by lines of different width).
The simulated scenarios investigated the probability with which the arrival (top panels) or decline (bottom panels) of the new strain could be
detected, see Methods. The circle corresponds to the most likely parameters of the 2006 outbreak.
doi:10.1371/journal.pmed.1001279.g006
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innate immune stimulation by different microbial strains will be
limited, although clearly such variant(s) may exist, and remain to
be discovered. In particular, we are not aware of published work
describing heterogeneity in the host response: mortality relation-
ship within members of a bacterial species. However, even if this
heterogeneity were to exist, a biomarker that was even a partial
surrogate for mortality could still provide substantial additional
power to detect severity changes over current methods that rely on
clinician suspicion or mortality monitoring.
What action should be taken on the basis of ‘signals’ from this
kind of surveillance? We suggest, on the basis of the experience
with C. difficile, one should not be particularly reassured if
anecdotal clinical opinion suggests there is ‘no obvious problem’,
while severity surveillance is identifying rising biomarker levels, as
heterogeneity of severity, low frequency of clinician contact with
particular infections, and the insidious nature of severity changes
may all militate against clinical detection. Rather, we would
advocate further analytical investigation(s). The requirement for
such additional study is a feature of much passive surveillance and
applies equally to more widely used techniques for monitoring
incidence and mortality; the investigation could be either
prospective or retrospective, perhaps across hospitals, and would
aim to identify whether patient characteristics, or strain charac-
teristics, were associated with the observed severity signal. In some
situations where microbiological diagnosis is rare, such as
pneumonia, it might involve enhanced sample collection. In such
investigations, modern molecular typing methods, which have very
high sensitivity for the detection of new strains [30], but also
identify much variation that is unrelated to severity, would likely
complement the sort of routine biomarker-based surveillance we
describe here, which is capable of monitoring severity changes in
organisms that are not routinely cultured, such as C. difficile.
There are also statistical issues related to the technique used in
this paper, which is not necessarily optimal: simultaneous use of
multiple measures of severity (such as neutrophil and creatinine
counts together), perhaps using Bayesian techniques, may offer
increased sensitivity and more rapid detection, without increase in
false positive results. Detailed comparison with existing change-
point detection algorithms [34–38] is planned. Preliminary results
suggest that at least in some scenarios, such as those described in
Figure 7. Comparison of secular changes in neutrophils across Oxford (top panels) and Birmingham (bottom panels) hospitals. Left
panels contain mean quarterly neutrophil counts, with 95% CIs shown in grey, and black lines representing the loess curves with the span parameter
set to 0.5. Right panels show changes in secular trends identified by ISR indicated by m (change from an upward to downward trend), and . (a
downward to an upward trend), with+indicating the point in time when this change in secular trend was first detected, and horizontal intervals
showing the range of joinpoints within 3.84 of the best model BIC at this time.
doi:10.1371/journal.pmed.1001279.g007
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the simulation study, ISR performance is superior to that of the
widely used scan-statistic based tool, SaTScan (unpublished data)
[39]. In contrast, SaTScan is superior for detecting highly localised
‘outbreaks’ [40], where changes are rapid and short-lived as
opposed to the more gradual changes that typically accompany
strain variation.
Independent of the optimal algorithm, however, we have shown
that monitoring severity of infection passively is feasible, can detect
important shifts in the phenotype of human pathogens, and offers
superior performance relative to mortality monitoring. Since
waves of virulence, as shown here with C. difficile, appear to be a
general feature of the evolution of human microbial pathogens [1–
4,10], we believe the approach described here, which we term
‘surveillance of severity’, will be applicable to many organisms and
syndromes.
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Editor’s Summary
Background. The ability of bacteria to cause infection and
disease (that is, their virulence) is in part determined by
bacterial genetic makeup. At any time, there is a great deal
of genetic diversity within common kinds of bacteria, which
naturally generate new variants all the time. Sometimes
organisms arise with a genetic makeup that causes more
severe infection in humans and even death. For example, in
2005, spread of a particularly virulent strain (called 027/ST1)
of the toxin-producing bacterium Clostridium difficile caused
a global epidemic of C. difficile infection.
Why Was This Study Done? In health care settings,
general methods of detecting changing virulence to enable
the early recognition, control, and optimal management of
increasingly severe infections would be highly beneficial.
Changing virulence of a bacterial infection is often measured
using death rates, but only a small proportion of those with
infection die from it, so this may not be the most sensitive
method of monitoring. Consequently, in this study the
researchers investigated whether the changing virulence of
C. difficile infection could be tracked by using common
clinical measurements (white blood cell count, neutrophil
count, blood urea, and creatinine concentrations, which
reflect how unwell patients are) as the basis of an infection-
severity surveillance scheme.
What Did the Researchers Do and Find? The researchers
examined all C. difficile toxin tests obtained from the
microbiological lab serving hospitals in Oxford, UK, between
February 1, 1998 and August 1, 2009. They also identified all
inpatients aged over 18 years with a positive C. difficile test
when admitted to hospitals over this time, examined their
laboratory blood tests, and noted recorded deaths. The
researchers used patients with C. difficile toxin-negative
samples as a control group. To further validate their analysis,
the researchers also undertook a similar analysis in a hospital
in another UK city (Birmingham).
The researchers used statistical models to estimate changes
in potential biomarkers (neutrophils, creatinine, and urea)
with reference to the C. difficile 2005 global epidemic and
post-infection death rates. The researchers used another
statistical model (an iterative sequential regression tech-
nique) to estimate how soon any changes in biomarker/
mortality trends would have been detected. Finally, to
evaluate these severity-monitoring techniques, the research-
ers performed two simulation studies in which they assumed
a more severe strain of C. difficile was introduced into a
hospital.
Using these methods, the researchers found that in
patients who were positive for C. difficile toxin, average
neutrophil counts on diagnosis increased from 2003,
peaked in 2006–2007, and then declined. They also found
that 28-day deaths from C. difficile infection increased from
early 2006, peaked in late 2006–2007, and then declined.
Furthermore, laboratory tests (molecular typing) confirmed
these changes were likely due to the severe C. difficile
strain. The simulation model derived from the observed
data suggested the performance of biomarker-based
detection was notably higher than that of monitoring
deaths post-infection.
What Do These Findings Mean? These findings suggest
that passively monitoring the severity of infection using
routinely measured clinical biomarkers is feasible and can
potentially detect important shifts in the virulence of human
pathogens, such as C. difficile. Furthermore, such a surveil-
lance system is superior to, and has obvious advantages
over, monitoring deaths from infection — provided bio-
marker data is available. It could be used to provide an early
trigger for more detailed investigations of patient charac-
teristics, complemented by studies of bacterial genetic
makeup, with the aim of tailoring policy and optimizing
treatment of infection. Although this study monitored only
one bacterial species, as changes in virulence are common to
most human pathogens, this surveillance of severity tech-
nique could be applied to other organisms.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001279.
N Wikipedia provides information about bacterial virulence
(note that Wikipedia is a free online encyclopedia that
anyone can edit; available in several languages)
N The World Health Organization provides the latest news on
infection outbreaks and epidemics
N The Centers for Disease Control and Prevention provide
information on C. difficile for health professionals and
patients
N Trends in C. difficile disease in England and Wales are
reported by the Health Protection Agency
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